Loading
Everything OnCo dates to 2027: 32 entries, 31 expected dates and 1 trial reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
32 dated entries in OnCo fall in 2027: 31 expected dates and 1 trial reported.
Of those, 9 to the day, 8 to the month, 3 to the quarter and 12 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The year reported on trial records, with the headline result the record gives.
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Expected date. Event-driven iDFS endpoint in patients with residual disease after KEYNOTE-522-type therapy. Would be the first ADC in the curative TNBC setting.
Expected date. Tests the ADC as the first chemotherapy after endocrine therapy. Timing is a registry-based estimate.
Expected date. Follows the 23 September 2026 advisory committee. PMA decisions typically come months after the panel; no date has been announced.
Expected date. The first head-to-head test of the PD-1 x VEGF bispecific against pembrolizumab in a Western population.
Expected date. Pivotal phase 3 for the B7-H3 ADC from the Merck and Daiichi Sankyo collaboration. Timing is a registry-based estimate.
Expected date. The first phase 3 comparing KRAS G12C inhibitors head to head. Timing is a registry-based estimate.
Expected date. The sponsors said filings would follow the positive topline result of August 2026 and the full data presentation. Timing is our estimate.
Expected date. Phase 2/3 for the CDH6 ADC. Timing is a registry-based estimate.
Expected date. Phase 3 in first-line KRAS G12C-mutant NSCLC. Timing is a registry-based estimate.
Expected date. Would move the TROP2 ADC into the first-line EGFR-mutant setting on top of the standard TKI. Timing is a registry-based estimate.
Expected date. Merck holds a Commissioner's National Priority Voucher (July 2026) that promises a 1 to 2 month review once filed.
Estimated primary completion date on ClinicalTrials.gov.
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...
Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.
Confirmed date. Early science and first-in-human data: next-generation ADC payloads, degraders, in vivo CAR-T.
Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.
Estimated primary completion date on ClinicalTrials.gov.
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Confirmed date. Where most practice-changing phase 3 trials are first presented.
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Expected date. Fully enrolled; event-driven OS endpoint. Sponsor has guided to a readout in 2026 or 2027. The first pivotal test of a pan-RAS inhibitor.
Expected date. Global first-line trial of the EGFR×HER3 bispecific ADC; timing is an estimate from enrolment start (2025).
Expected date. Registry estimated primary completion 20 September 2027; topline may lag.